We are live on ! Find out more
RXRX icon

Recursion Pharmaceuticals
RXRX

128 hedge funds and large institutions have $680M invested in Recursion Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 40 increasing their positions, 37 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more call options, than puts

Call options by funds: $321K | Put options by funds: $278K

14% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 21

2% more funds holding

Funds holding: 126 → 128 (+2)

8% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 37

0.39% less ownership

Funds ownership: 59.14% → 58.75% (-0.39%)

25% less funds holding in top 10

Funds holding in top 10: 8 → 6 (-2)

58% less capital invested

Capital invested by funds: $1.62B → $680M (-$935M)

Holders
128
Holders Change
+2
Holders Change %
+1.59%
% of All Funds
2.02%
Holding in Top 10
6
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-25%
% of All Funds
0.09%
New
24
Increased
40
Reduced
37
Closed
21
Calls
$321K
Puts
$278K
Net Calls
+$43K
Net Calls Change
-$1.11M

Top Buyers

1
Citadel Advisors
Citadel Advisors
Florida
+$7.55M
2
PIM
Platinum Investment Management
Australia
+$7.36M
3
LCM
Laurion Capital Management
New York
+$7.05M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$6.54M
5
AIM
ARK Investment Management
Florida
+$6.33M

Top Sellers

1
State Street
State Street
Massachusetts
-$29.1M
2
PC
PointState Capital
New York
-$7.02M
3
BAMCO Inc
BAMCO Inc
New York
-$7M
4
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group
Japan
-$6.32M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$3.14M
Name Holding Trade Value Shares
Change 		Change in
Stake
Baillie Gifford & Co
1
Baillie Gifford & Co
United Kingdom
$157M -$1.5M -141,551 -0.6%
BlackRock
2
BlackRock
New York
$48M -$584K -54,927 -0.8%
Vanguard Group
3
Vanguard Group
Pennsylvania
$47.3M +$5.29M +497,504 +8%
OMS
4
Obvious Management Services
California
$42.8M – – –
DCI
5
Data Collective IV
California
$42.5M – – –
LCM
6
Laurion Capital Management
New York
$32.8M +$7.05M +663,561 +17%
DOFI
7
DCVC Opportunity Fund II
California
$28.3M – – –
AllianceBernstein
8
AllianceBernstein
Tennessee
$24.2M +$5.37M +504,899 +18%
AIM
9
ARK Investment Management
Florida
$20.2M +$6.33M +595,150 +27%
Fidelity Investments
10
Fidelity Investments
Massachusetts
$15.4M +$6.54M +615,413 +40%
PIM
11
Platinum Investment Management
Australia
$15.3M +$7.36M +692,741 +48%
MMX
12
MV Management XI
California
$14.1M – – –
State Street
13
State Street
Massachusetts
$13.7M -$29.1M -2,737,993 -59%
TSV
14
Two Sigma Ventures
New York
$12.9M – – –
CS
15
Credit Suisse
Switzerland
$11.2M +$53K +4,984 +0.3%
HMC
16
Harvard Management Company
Massachusetts
$10.8M – – –
Norges Bank
17
Norges Bank
Norway
$10M +$11 +1 +0%
MCMU
18
MIC Capital Management (UK)
United Kingdom
$9.94M – – –
Massachusetts Financial Services
19
Massachusetts Financial Services
Massachusetts
$9.57M +$390K +36,709 +3%
Geode Capital Management
20
Geode Capital Management
Massachusetts
$9.26M -$12.8K -1,201 -0.1%
AI
21
ArchPoint Investors
Florida
$9.07M +$128K +12,000 +1%
CFM
22
Comprehensive Financial Management
California
$7.94M – – –
Citadel Advisors
23
Citadel Advisors
Florida
$6.51M +$7.55M +710,363 +356%
Northern Trust
24
Northern Trust
Illinois
$6.15M -$281K -26,417 -3%
T. Rowe Price Associates
25
T. Rowe Price Associates
Maryland
$4.03M -$3.14M -295,383 -34%
1
2 3 4 5

RXRX Hedge Fund Activity: Q1 2022 in Review

128 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q1 2022, worth a combined $680M — down 58% from $1.62B a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new RXRX positions and 21 closed out — a net gain of 3 holders — while 40 added to existing stakes and 37 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $7.55M. The largest seller was State Street, cutting an estimated $29.1M.

  • 128 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q1 2022, up from 126 in Q4 2021.
  • Funds reported $680M of Recursion Pharmaceuticals stock for Q1 2022, down 58% quarter-over-quarter.
  • 24 funds opened new Recursion Pharmaceuticals positions in Q1 2022 and 21 closed out, a net change of +3 holders.
  • The largest Recursion Pharmaceuticals buyer in Q1 2022 was Citadel Advisors, an estimated $7.55M added.
  • The largest Recursion Pharmaceuticals seller in Q1 2022 was State Street, an estimated $29.1M sold.

Based on aggregated 13F filings for Q1 2022.